Oct 7 (Reuters) – Health insurer Anthem Inc said it
would not cover the first U.S. Food and Drug
Administration-approved Duchenne muscular dystrophy (DMD) drug,
developed by Sarepta Therapeutics Inc,…
The post Anthem won’t cover first FDA-approved Duchenne drug appeared first on NASDAQ.